CAS 212316-88-6

Losartan Related Compound E (4'-[({2-Butyl-5-[(5-{4'-[(2-butyl-4-chloro-5-hydroxymethyl-1H-imidazol-1-yl)methyl]biphenyl-2-yl}-2H-tetrazol-2-yl)methyl]-4-chloro-1H-imidazol-1- yl}methyl)biphenyl-2-yl]tetrazol, potassium salt)

CAS : 212316-88-6

Compounds containing an unfused imidazole ring, whether or not hydrogenated, in the structure, nesoi

Formule : C₄₄H₄₃Cl₂KN₁₂O

Couleur et forme : Powder

Masse moléculaire : 864.26969

Ref: 45-1370510

Potassium 5-[4'-[[2-Butyl-4-chloro-5-[5-[4'-[[2-Butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]biphenyl-2-yl]tetrazol-2-yl]methyl-1H-imidazol-1-yl]methyl]biphenyl-2-yl]tetrazolide

CAS : 212316-88-6

Couleur et forme : Neat

Ref: 86-MM0168.33

N2-Losartanyl-losartan (Losartan Impurity) Potassium Salt

Produit contrôlé

CAS : 212316-88-6

Formule : C₄₄H₄₃Cl₂N₁₂O·K

Couleur et forme : White To Off-White

Masse moléculaire : 865.90

Ref: TR-L470615

Losartan related compound E

CAS : 212316-88-6

Losartan is a drug that is used to treat high blood pressure and congestive heart failure. It is an angiotensin II receptor antagonist that blocks the binding of angiotensin II to its receptor, preventing the activation of protein kinase A and the release of aldosterone. Losartan is also known as losartan-related compound E (LZE). LZE has been shown to have a papain-like protease activity with a light chain. This activity may be responsible for its anti-diabetic effects. LZE has been shown to inhibit hyperglycemia in mice by reducing serum glucose levels and increasing insulin sensitivity. In addition, LZE has been shown to reduce cardiac death in rats by activating nuclear factor erythroid 2-related factor 2 (Nrf2), which induces expression of antioxidant enzymes such as heme oxygenase 1 and superoxide dismutase 1 (SOD1).

Formule : C₄₄H₄₃Cl₂KN₁₂O

Degré de pureté : Min. 95%

Masse moléculaire : 865.9 g/mol

Ref: 3D-MIA31688